$17.89
+1.35 (+8.16%)
Open$17.21
Previous Close$16.54
Day High$19.36
Day Low$16.62
52W High$29.16
52W Low—
Volume—
Avg Volume215.7K
Market Cap966.94M
P/E Ratio—
EPS$-0.87
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.53M | 9.1K | 117.17M |
| Net Income | -45,163,515 | -50,362 | -10,038,830 |
| Profit Margin | -2,957.6% | -582.6% | -8.6% |
| EBITDA | -51,868,084 | -48,936 | -16,056,956 |
| Free Cash Flow | — | — | -11,744,338 |
| Rev Growth | +147.5% | +60.5% | +1.7% |
| Debt/Equity | — | 0.51 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |